AK-I-190, a New Catalytic Inhibitor of Topoisomerase II with Anti-Proliferative and Pro-Apoptotic Activity on Androgen-Negative Prostate Cancer Cells

Castration-resistant prostate cancer (CRPC) is a clinical challenge in treatment because of its aggressive nature and resistance to androgen deprivation therapy. Topoisomerase II catalytic inhibitors have been suggested as a strategy to overcome these issues. We previously reported AK-I-190 as a nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Kyung-Hwa, Park, Seojeong, Jang, Hae Jin, Hwang, Soo-Yeon, Shrestha, Aarajana, Lee, Eung-Seok, Kwon, Youngjoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538266/
https://www.ncbi.nlm.nih.gov/pubmed/34681904
http://dx.doi.org/10.3390/ijms222011246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538266/
https://www.ncbi.nlm.nih.gov/pubmed/34681904
http://dx.doi.org/10.3390/ijms222011246

Ejemplares similares